Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.

What Is the Growth Rate of the Cancer Tumor Profiling Market?

The market size for cancer tumor profiling has seen a significant expansion in the recent past. It is set to grow from a value of $13 billion in 2024 to a larger value of $14.99 billion in 2025, experiencing a compound annual growth rate (CAGR) of 15.3%. The surge in numbers during the historic period is linked with the rising incidence of cancer, advancements in precision medicine initiatives and research partnerships, enhanced cancer diagnostic techniques and early detection methodologies, an abundance of targeted therapy alternatives, and a favorable regulatory environment for cancer profiling examinations.

What Growth Rate Is Forecasted for the Cancer Tumor Profiling Market by 2029?

The market size of cancer tumor profiling is predicted to experience significant growth in the forthcoming years, increasing to $25.33 billion in 2029 with a compound annual growth rate (CAGR) of 14.0%. The projected rise is attributable to the broader implementation of immunotherapy and immunoprofiling in cancer treatment, advancements in liquid biopsy and non-invasive tumor profiling techniques, the employment of single-cell sequencing for comprehensive tumor profiling, growth in cancer screening and early detection initiatives, and heightened demand for the profiling of rare and orphan cancer subtypes. Key trends for the forecast period feature the incorporation of tumor profiling into standard clinical procedures, progress in multi-omics methodologies, the application of artificial intelligence (AI) and machine learning in data interpretation, tailoring of medicine and treatment based on individual needs, and progression in genomics and next-generation sequencing (NGS) technologies.

Download The Free Sample Report Here:

https://www.thebusinessresearchcompany.com/sample.aspx?id=6053&type=smp

Which Key Companies Are Shaping the Future of the Cancer Tumor Profiling Market?

Major companies operating in the cancer tumor profiling market include F. Hoffmann-La Roche Ltd., Caris Life Sciences, Thermo Fisher Scientific Inc., Illumina Inc., Qiagen, Ribomed Biotechnologies Inc., HTG Molecular Diagnostics Inc., NanoString Technologies Inc., NeoGenomics Laboratories Inc., Lucence Health Inc., ACT Genomics Co. LTD, Strand Life Sciences, IMB Dx Inc., Exact Sciences Corporation, Guardant Health, Foundation Medicine Inc., Agilent Technologies Inc., Myriad Genetics Inc., Personal Genome Diagnostics Inc., Tempus Labs Inc., ArcherDX Inc., Natera Inc., Bio-Rad Laboratories Inc., Genetron Health, NantHealth Inc., Resolution Bioscience, Genomic Testing Cooperative, OncoDNA, Strata Oncology Inc., Genuity Science, RareCyte Inc., Inivata Limited, Cepheid

Which Factors Are Driving Demand in the Cancer Tumor Profiling Industry?

The global surge in cancer cases is anticipated to fuel the expansion of the cancer and tumor profiling market. Cancer, a condition characterized by uncontrolled cell growth and spread, is seeing a rise in prevalence, triggering an increased demand for cancer tumor profiling. This technique helps physicians assess the disease’s severity. For example, in 2024, the American Cancer Society, based in the US, disclosed that cancer diagnoses rose to 2 million from 1.9 million in the previous year. Consequently, the escalating frequency of cancer worldwide propels the progress of the cancer and tumor profiling market.

Request For A Customized Report:

https://www.thebusinessresearchcompany.com/customise?id=6053&type=smp

How Is the Cancer Tumor Profiling Market Segmented by Several Divisions?

The cancer tumor profiling market covered in this report is segmented –

1) By Cancer Type: Lung Cancer, Breast Cancer, Colorectal Cancer, Prostate Cancer, Melanoma, Ovarian Cancer, Stomach Cancer, Pancreatic Cancer, Thyroid Cancer, Other Cancer Types

2) By Technology: Next-Generation Sequencing (NGS), Polymerase Chain Reaction (PCR), Immunohistochemistry (IHC), In Situ Hybridization (ISH), Microarray, Other Technologies

3) By Process Type: Genomics, Proteomics, Epigenetics, Metabolomics, Other Types

4) By Application: Personalized Medicine, Diagnostics, Biomarker Discovery, Prognostics, Research Applications

Subsegments:

1) By Lung Cancer: Non-Small Cell Lung Cancer (NSCLC), Small Cell Lung Cancer (SCLC)

2) By Breast Cancer: Hormone Receptor-Positive, Triple-Negative Breast Cancer, HER2-Positive Breast Cancer

3) By Colorectal Cancer: Colon Cancer, Rectal Cancer

4) By Prostate Cancer: Localized Prostate Cancer, Advanced Prostate Cancer

5) By Melanoma: Cutaneous Melanoma, Non-Cutaneous Melanoma

6) By Ovarian Cancer: Epithelial Ovarian Cancer, Non-Epithelial Ovarian Cancer

7) By Stomach Cancer: Gastric Adenocarcinoma, Gastrointestinal Stromal Tumors (GISTs)

8) By Pancreatic Cancer: Exocrine Pancreatic Cancer, Neuroendocrine Tumors

9) By Thyroid Cancer: Papillary Thyroid Cancer, Follicular Thyroid Cancer, Medullary Thyroid Cancer

10) By Other Cancer Types: Kidney Cancer, Bladder Cancer, Liver Cancer, Esophageal Cancer

What are the Emerging Market Trends Driving the Growth of the Cancer Tumor Profiling Industry?

The escalating activities in research and development are emerging as a leading trend in the cancer and tumor profiling market. Leading companies in the sector are investing heavily in research and development in order to satisfy consumer demands and solidify their market position. For example, QIAGEN N.V, a German firm specializing in sample and assay technology for applied testing, pharmaceutical development, molecular diagnostics, and academic research recently announced the Conformitè Europëenne (CE) – marking and commercial rollout of their therascreen PIK3CA RGQ PCR Kit in Europe. This kit is designed to assist in identifying breast cancer patients with PIK3CA mutations. The therascreen PIK3CA test is a diagnostic tool for the detection of an activating mutation in the phosphatidyl 3-kinase catalytic subunit alpha (PIK3CA) gene, and it’s the first to permit testing of DNA from either plasma specimens or FFPE tissue.

Access The Full Report Here:

https://www.thebusinessresearchcompany.com/report/cancer-tumor-profiling-global-market-report

Which Regions Are Driving Growth in the Cancer Tumor Profiling Market?

North America was the largest region in cancer and tumor profiling market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the cancer tumor profiling market report include Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Purchase The Full Report Today:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=6053

This Report Delivers Insight On:

1. How big is the cancer tumor profiling market, and how is it changing globally?

2. Who are the major companies in the cancer tumor profiling market, and how are they performing?

3. What are the key opportunities and risks in the cancer tumor profiling market right now?

4. Which products or customer segments are growing the most in the cancer tumor profiling market?

5. What factors are helping or slowing down the growth of the cancer tumor profiling market?

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model